

Raynar Flagship

Factsheet
July 2021

Sub Fund of : EFG Silverstone SICAV-RAIF

Fund Manager:



Portfolio Manager:

Philip Rodriqs

First Day of Trading:

1 June 2020

Fund Assets Under

Management:

£47.2m

Firm Assets Under

Management

£104.4m

Custodian:

EFG Bank (Luxembourg) S.A.

AIFM

EFG Fund Management S.A.

Administrator:

HSBC France,
Luxembourg Branch


Auditor:

BDO Audit S.A. Luxembourg

Fund Objective:

To achieve capital growth over the medium term with an absolute focus on stock selection, unconstrained in its approach to building a high conviction portfolio of attractive risk vs return high conviction investments from across the UK equity market, with a likely predominance of small and micro sized companies. During periods with insufficient opportunities, unallocated capital will be preserved utilising the flexibility to invest in cash, beta hedging instruments and other asset classes.

FOR PROFESSIONAL INVESTORS ONLY



	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Calendar Return	Total Return
2020						3.57%	6.50%	7.16%	-3.35%	-0.46%	10.83%	11.69%	40.75%	
2021	+1.42%	7.92%	4.75%	6.67%	2.83%	-2.97%	3.07%						25.79%	77.05%

Past performance is not a reliable indicator of future performance. *Raynar Flagship performance shows the net asset values of Class A Distribution shares in GBP from launch sourced from Bloomberg net of all fees and costs and excluding dividends.

The investment strategies employed by Raynar Portfolio Management are intended only for those persons who may be categorised as professional clients. Raynar Portfolio Management is a trading name of Met Facilities LLP which is authorised and regulated by the Financial Conduct Authority (FRN: 587084). Met Facilities LLP is the investment manager of the Fund. EFG Fund Management SA is the Alternative Investment Fund Manager (AIFM).

Raynar Flagship

Factsheet
July 2021

Sub Fund of : EFG Silverstone SICAV-RAIF

Top Ten Equities	Holding	Top Ten Investment Themes	Allocation
MaxCyte	10.9%	Medical Technology	16.5%
Future	4.0%	UK Internet Retail	15.2%
Reach	3.3%	Structural/Defensive Growth	12.3%
OneSavings Bank	3.1%	UK Financial Services	12.1%
Studio Retail	3.0%	UK Housing & Construction	11.6%
Vistry	3.0%	Raw Materials	10.3%
Gear4Music	2.9%	UK & Global Consumer	10.0%
In The Style	2.9%	Media	9.1%
K3 Capital	2.8%	Next Generation Technology	6.0%
Capital Drilling	2.4%	Excess High Conviction*	-3.2%

MaxCyte – The UK market's Nasdaq Unicorn

The term 'unicorn' is generally applied to a start-up firm that reaches a billion dollar valuation. Whilst **MaxCyte**, which listed in the UK in 2016 at a c\$50m valuation, wasn't strictly speaking a start-up by that point, it was very much at the beginning of what has already been an exciting and rewarding journey. Nurtured on the UK AiM market, **MaxCyte** took a huge stride forward by completing its dual-listing IPO onto the US Nasdaq exchange at the end of this month, valuing the firm at over \$1.1bn. Is **MaxCyte** still undervalued c550% ahead of our initial in-price?

In recent decades there have been waves of innovation as fundamental new discoveries lead to major new classes of treatments. At the cutting edge is a new method which uses a patient's own blood cells to fight disease. By taking a patient's own blood, inserting a drug or a DNA instruction into hundreds of millions of those blood cells and returning them to the patient (with much reduced rejection risk), the patient's own cells can fight disease. Despite sounding like science fiction, early examples of this new class of therapy are producing very significant results.

So how do you inject DNA instructions into billions of cells? Some use a modified virus, which takes many days. **MaxCyte's** unique and patented Flow Electroporation technology can use electrical pulses to deliver the payload within a day – a game-changer that has seen **MaxCyte** sign up a succession of industry leaders to their roster. Can **MaxCyte** really have a globally significant medical technology platform that could enable countless therapies and cures? It may seem like a story that's too good to be true; however MaxCyte continues to be held with the same degree of conviction as that demonstrated by the firm's customers.

Contact Details

Head of Client Relations:

Jon Garland

jon@raynarpm.com

T: 0207 1234 606

M: 0745 809 2791

Websites:

www.raynarpm.com

Enquiries Form:

www.raynarpm.com/investor-enquiries/

Raynar Flagship Share Classes	A Class	B Class
Inception Date	29 th May 2020	24 th August 2020
Status	Open	Open
Minimum Initial Investment	£200,000	£5,000,000
Subscription	Daily, zero fee	Daily, zero fee
Redemption	Monthly, zero fee	Monthly, zero fee
Redemption Notice**	20 Business Days	20 Business Days
Annual Management Charge	1.00%	0.75%
Performance Fee	20%	20%
Hurdle Rate	5% annualised	10% annualised
High Water Mark	Yes – Lifetime	Yes – Lifetime
Distribution/Accumulation	Distribution	Distribution
ISIN	LU2076760391	LU2203806885
Bloomberg Ticker	EFSTRFGI LX	EFSTRFBG LX

*Redemptions processed last business day each month – instruction required before 3pm UK time on last business day of the prior month

Investment Themes are categorisations chosen by the portfolio manager which, in their opinion, best describes the predominant driver of the underlying investments. Investments may be re-categorised. *Represents negative cash balance arising from the utilisation of leverage to accommodate periods where there are excess high conviction investment ideas

Information for investors in Switzerland: The Fund mentioned in this marketing material is not approved by FINMA for offering to non-qualified investors in Switzerland and the information presented is only for qualified investors as defined under art. 10 paragraph 3 and 3ter CISA in connection with art. 4 paragraphs 3 to 5 FinSA and art. 5 paragraphs 1 and 4 FinSA. The Representative in Switzerland is CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The Paying Agent in Switzerland is CACEIS Bank, Paris, Nyon Branch / Switzerland, Route de Signy 35, CH-1260 Nyon. The prospectus, the key investor information document, the articles of association and the annual and semi-annual reports of the Fund/s may be obtained, free of charge, at the representative in Switzerland. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units.